دورية أكاديمية

Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines

التفاصيل البيبلوغرافية
العنوان: Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines
المؤلفون: Pardeike, Jana1 jana.pardeike@uni-graz.at, Strohmeier, Daniela M.1,2, Schrödl, Nina2, Voura, Christine2, Gruber, Michael2, Khinast, Johannes G.2, Zimmer, Andreas1
المصدر: International Journal of Pharmaceutics. Nov2011, Vol. 420 Issue 1, p93-100. 8p.
مصطلحات موضوعية: *PRINTING ink, *DRUG solubility, *MEDICAL model, *FOLIC acid, *SUSPENSIONS (Chemistry), *ASYMPTOTIC homogenization, *NANOSTRUCTURED materials
مستخلص: Abstract: Folic acid was used as a model drug to demonstrate the advantages of formulating poorly soluble drugs as nanosuspensions and their use in an inkjet-type printing technique to produce personalized medicines. 10% folic acid nanosuspensions stabilized with Tween 20, a stabilizer showing the best wetting potential for folic acid, were prepared via high pressure homogenization. The particle size of the folic acid nanosuspension was well below 5μm being a prerequisite for inkjet type printing technique. A good reproducibility of the particle size of folic acid nanosuspension prepared via high pressure homogenization was found. As indicated by the zeta potential the formulation showed a good storage stability. High pressure homogenization had no influence on the crystalline state of folic acid. An increase in the saturation solubility by 53.7% was found reducing the particle size from the micrometer range to the nanometer range. The dissolution velocity of the folic acid nanosuspension was significantly enhanced compared to a folic acid suspension, i.e. after 5min 78.6% of the folic acid was dissolved from the nanosuspension and only 6.2% from the suspension. Moreover, the printing of 10% folic acid nanosuspension could be successfully demonstrated. [Copyright &y& Elsevier]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:03785173
DOI:10.1016/j.ijpharm.2011.08.033